Abstract
Phytochemists nowadays have growing interests on medicinal plants which have pharmacological activities. Therefore, investigation on biological active secondary metabolites from the root bark of Mesua ferrea (Clusiaceae) was scrutinized. A series of polyphenolic derivatives were obtained from our ongoing research where three of which were new: mesuaferrin A 1, mesuaferrin B 2 and mesuaferrin C 3. The known compounds were identified as caloxanthone C 4, 1,5-dihydroxyxanthone 5 and tovopyrifolin C 6. Structures of these compounds were elucidated by extensive spectroscopic methods which include 1D and 2D-NMR, GC-MS and IR techniques. Preliminary insights on in vitro cytotoxicity and structure-activity relationships of all the isolated metabolites against a panel of human cancer cell lines including Raji (human B lymphocyte), SNU-1 (human gastric carcinoma), K562 (human erythroleukemia cells), LS-174T (human colorectal adenocarcinoma), HeLa (human cervical cells), SK-MEL-28 (human malignant melanoma cells), NCI-H23 (human lung adenocarcinoma), IMR-32 (human neuroblastoma) and Hep-G2 (human hepatocellular liver carcinoma) were performed using MTT assay. Compounds 1 - 5 exhibited significant (IC50 values ranging from 0.1 to 9.4 µg/mL) cell proliferation inhibition against all the tested cancer cells. The phytochemical and pharmacognosy investigation showed adverse effects of polyphenolic compounds suggesting that Mesua ferrea could be a phytotheraupic source of lead compounds in drug discovery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.